Posts tagged “Intersouth”

Updated May 30, 2013

Premium Lock More than ever, 'City of Medicine' fits Durham's new economy

New Bull City, Day Eight: In 1988, Durham had just four total life science companies. Now the city has 92 firms and counting. Read how the life sciences took root in the "City of Medicine" as WRALTechWire's report about the rebirth of Durham continues.

From tobacco to biotech ... From tobacco to biotech ...

Updated May 29, 2013

Premium Lock Biotech in Durham builds on Venable building's history

Venable Center The New Bull City: A former tobacco building now houses several life science related firms, and space once used to process tobacco now offers research space. The history of the Venable center reflects Durham,s transition from a tobacco town to a tech hub.

Updated May 29, 2013

Premium Lock A chef and venture capitalist says food helps spark Durham innovation

New Bull City: Durham's rise as a technology and life sciences hub owes something to the city's emergence as a food town. A Durham venture capitalist explains.

Food is helping fuel Durham's rebirth. Food is helping fuel Durham's rebirth.

Updated April 10, 2013

Premium Lock Advanced Animal Diagnostics raises $6M in new funding

AAD Intersouth Partners, Novartis and other investors pour $6 million in new funding into Durham-based Advanced Animal Diagnostics for launch of two products.

December 13, 2012

Premium Lock Semiconductor firm HexaTech wins $2.2M federal contract for new type of chips

HexaTech, a venture capital backed company, wins federal funding to develop a new kind of chip for the nation's power grid.

HexaTech graphic explains its chip focus HexaTech graphic explains its chip focus

November 20, 2012

Premium Lock Intersouth puts more money in Florida genetics startup

Intersouth Durham-based Intersouth Partners joins four other investors as part of a $37.5 million B round of financing for Applied Genetic Technologies.

November 14, 2012

Premium Lock Raleigh 'cloud' startup seeking $4M in new financing

6fusion, which is backed by Intersouth partners, has raised $2 million in a mix of debt and options financing. The company hopes to raise $2 million more.

6fusion's "Cube" concept for managing the "cloud" 6fusion's "Cube" concept for managing the "cloud"

Updated September 12, 2012

Premium Lock Chapel Hill drug startup Vascular Pharma raises $16M

The company also strikes a deal to sell the firm after a future clinical trial to Janssen Biotech. Intersouth Partners, MPM lead the first round of financing for Vascular, which is focused on development of treatments for diabetes complications.

Vascular Pharma Vascular Pharma

August 30, 2012

Premium Lock Semiconductor firm HexaTech raises $500,000 in debt financing

The venture capital backed startup, which has been funded locally by Intersouth Partners and NCIDEA, is commercializing technology developed at NC State.

HexaTech graphic explains its chip focus HexaTech graphic explains its chip focus

Updated August 22, 2012

Premium Lock Can reborn Zenph strike winning chord this time?

ZOEN Venture capital firm Intersouth Partners keeps faith in Zenph Sound Innovations, which shut down and was reborn as Online Music Network.

August 15, 2012

Premium Lock Startup Zenph relaunches as music online learning platform

ZOEN Backed by $900,000 in new financing with Intersouth Partners as the lead investor, a new company emerges from the assets of Zenph Sound Innovations.

August 2, 2012

Premium Lock Zenph Sound Innovations reboots as Online Music Network

Zenph According to an SEC filing and Intersouth Partners, Zenph has raised $450,000 and is going forward with a new business plan.

Updated July 23, 2012

Premium Lock Despite surge in tech startups, VCs see little chance of a 'bubble'

Venture Update With all the recent programs rolling out to support the launch and growth of new companies, funding remains scarce. If nothing else, lack of cash will keep a damper on entrepreneurs' hopes of flaming beyond control.

Updated July 6, 2012

Premium Lock Biotech firm Biolex, which raised $160M, seeks bankruptcy

The biotechnology firm, backed by Intersouth Partners which is owed some $5 million, has been seeking to development treatments for hepatitis C. Biolex raised $60 million in 2008 in one of the state's biggest venture capital deals. It tried and failed to go public that same year.

Biolex worker eyes lemna plants. Biolex worker eyes lemna plants.

Updated May 1, 2012

Premium Lock Shine on: Durham solar firm Semprius cracks MIT top 10 tech list

The startup company's leading-edge solar technology "could soon make electricity cheaply enough to compete with power plants fueled by coal and natural gas," says the Massachusetts Institute for Technology in its annual "most important technology milestones" list.

Semprius' solar panel technology Semprius' solar panel technology

April 24, 2012

Premium Lock Argos Therapeutics raises $25M after withdrawing IPO

The Durham-based drug development firm lands a new investor as well as more backing from Intersouth and Aurora Funds. The deal follows Argos' recent decision to terminate plans to go public.

Argos process Argos process

March 2, 2012

Premium Lock Biolex sale is an option, CFO tells Triangle Business Journal

Biolex worker eyes lemna plants. The company is looking for drug-development partners but a sale is possible, chief financial officer says.

February 20, 2012

Premium Lock Triangle may draw interest from more life science investors

Venture Briefs Talk can be cheap, of course, and investors who look to Research Triangle Park have been pretty predictable over the years. But some new faces showed up at the CED Life Science Conference - and some familiar ones returned.

Updated February 16, 2012

Premium Lock Argos Therapeutics aims for as much as $79M in IPO

The Durham based venture capital-backed firm estimated an IPO price of between $13 and $15 per share. Some 5.25 million shares will be offered.

Argos process Argos process

February 10, 2012

Premium Lock $40M Aldagen deal is no quick exit for its investors

Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective regenerative medicine therapies for its pipeline. But a payoff remains in the future and depends on drug trial results.

Aldagen's pipeline Aldagen's pipeline

Techwire Inside Partners
The Skinny: A Blog by Rick Smith